Skip to main content

Table 1 Antimicrotubule trials.

From: Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Trial N randomized/evaluable Treatment arms (dose) and schedule Duration
Tannock, 2004 [64] 1006/1006 docetaxel (75 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily dexamethasone (8 mg) at 12, 3, and 1 hr(s) prior to infusion 10 cycles
   docetaxel (30 mg/m2) iv q wk for 5 wks prednisone (5 mg) po twice daily dexamethasone (8 mg) at 1 hr prior to infusion 5 cycles
   mitoxantrone (12 mg/m2) iv q 3 wks prednisone (5 mg) po twice daily 10 cycles
Petrylak, 2004 [63] 770/666 docetaxel (60 mg/m2)* iv q 3 wks EMP (280 mg) po thrice daily q 3 wks dexamethasone (20 mg) po thrice daily q 3 wks 12 cycles
   mitoxantrone (12 mg/m2)* iv q 3 wks prednisone (5 mg) po twice daily q 3 wks  
Abratt, 2003 [62] 451/414 vinorelbine (30 mg/m2) iv q 3 wks hydrocortisone (40 mg) ± AGM (1000 mg)† daily to progression
   hydrocortisone (40 mg) ± AGM (1000 mg)† daily  
Berry, 2001 [84] 166/NR paclitaxel (100 mg/m2) iv q 4 wks EMP (280 mg) po thrice daily NR
   paclitaxel (100 mg/m2) iv q 4 wks  
Hudes, 1999 [61] 201/193 vinblastine (4 mg/m2) iv q wk for 6 of 8 wks EMP (600 mg/m2) po daily (2 or 3 divided doses) to progression
   vinblastine (4 mg/m2) iv q wk for 6 of 8 wks  
Iversen, 1997 [65] 131/129 EMP (560 mg) po daily (2 divided doses) as long as tolerated by patient
   placebo po daily  
Johansson, 1991 [66] 105/102 MPA (1000 mg) im daily (d1-15), then im weekly to progression
   EMP (280 mg) po twice daily  
De Kernion, 1988 [67] 220/203 EMP (600 mg/m2) po (3 divided doses) NR
   flutamide (0.25 gm) po thrice daily  
Murphy, 1979 [68] 135/116 EMP (600 mg/m2) po daily (3 divided doses) prednimustine (30 mg) po daily (3 divided doses) q wk to progression
   prednimustine (30 mg) po daily (3 divided doses) q wk  
  1. *Docetaxel could be increased to 70 mg/m2 and mitoxantrone could be increased to 14 mg/m2 if no grade 3 or 4 toxicities were observed in cycle 1; †decision to use AGM was at the discretion of participating centers.
  2. Abbreviations: AGM – aminoglutethimide; d – day; EMP – estramustine phosphate; hr – hour; im – intra muscular; iv – intravenous; mg – milligrams; MPA – medroxyprogesterone acetate; m2 - meters squared; N – number; NR – not reported; po – per oral; q – every; wk(s) – week (s).